CEO David Campbell was paid $13,506,231 in fiscal year 2025, ↑ up 50.5% from fiscal year 2024, the 86th percentile of its disclosed peer group (SEC filing 0001193125-26-187095 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$13,506,231 ↑ David Campbell total, FY2025 | 86th CEO pay percentile vs peers | 30:1 CEO-to-median pay ratio | 90.33% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
JANX's next annual pay disclosure, estimated May 1, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Campbell | $680,000 | $0 | $0 | $12,459,031 | $367,200 | $0 | $0 | $13,506,231 |
| President and Chief Executive Officer | ||||||||
| Byron Robinson | 362,728 | 0 | 0 | 4,306,826 | 0 | 0 | 394,081 | 5,063,635 |
| Former Chief Strategy Officer | ||||||||
| Janeen Doyle | 309,963 | 75,000 | 995,280 | 3,124,983 | 114,066 | 0 | 50,000 | 4,669,292 |
| Chief Corporate and Business Development Officer | ||||||||
| Zachariah McIver | 475,000 | 0 | 0 | 3,999,195 | 165,300 | 0 | 0 | 4,639,495 |
| Former Chief Medical Officer | ||||||||
| Thomas DiRaimondo | 478,000 | 0 | 0 | 3,691,565 | 175,904 | 0 | 0 | 4,345,469 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Campbell | $13,506,231 | $8,974,873 | $4,193,269 | ↑ +4,531,358 |
| Byron Robinson | 5,063,635 | 3,815,641 | 1,740,990 | ↑ +1,247,994 |
| Janeen Doyle | 4,669,292 | — | — | — |
| Zachariah McIver | 4,639,495 | — | — | — |
| Thomas DiRaimondo | 4,345,469 | 3,414,644 | — | ↑ +930,825 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Janux Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper JANX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name JANX as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Byron Robinson | Chief Strategy Officer | $5,063,635 |
| David Campbell | CEO | $13,506,231 |
| Janeen Doyle | Executive | $4,669,292 |
| Thomas DiRaimondo | Chief Scientific Officer | $4,345,469 |
| Zachariah McIver | Chief Medical Officer | $4,639,495 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alana McNulty | Independent Director | $379,841 |
| Eric Dobmeier | Independent Director | $376,091 |
| Jake Simson, Ph.D | Independent Director | $381,591 |
| Natasha Hernday | Independent Director | $374,216 |
| Ron Barrett, Ph.D | Chair of the Board | $420,779 |
| Sheila Gujrathi, M.D | Independent Director | $370,466 |
| Vickie Capps | Independent Director | $389,216 |
| Winston Kung | Independent Director | $379,841 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Maria Dobek | Vice President, Accounting | 2026-05-11 | D | 2,038 | $14 | $28,878 | Common | Form 4 ↗ |
| Janeen Doyle | Chief Corp. & Bus. Dev. Ofcr | 2026-06-02 | D | 4,059 | 14 | 56,944 | Common, open-market sale | Form 4 ↗ |
| Ronald W. Barrett | Director | 2026-06-11 | A | 5,500 | 0 | 0 | RSU | Form 4 ↗ |
| Natasha Hernday | Director | 2026-06-11 | A | 15,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natasha Hernday | Director | 2026-06-11 | A | 5,500 | 0 | 0 | RSU | Form 4 ↗ |
| Winston Kung | Director | 2026-06-11 | A | 5,500 | 0 | 0 | RSU | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-06-11 | A | 15,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-06-11 | A | 5,500 | 0 | 0 | RSU | Form 4 ↗ |
| Jake Simson | Director | 2026-06-11 | A | 5,500 | 0 | 0 | RSU | Form 4 ↗ |
| Jake Simson | Director | 2026-06-11 | A | 15,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald W. Barrett | Director | 2026-06-11 | A | 15,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vickie Capps | Director | 2026-06-11 | A | 15,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vickie Capps | Director | 2026-06-11 | A | 5,500 | 0 | 0 | RSU | Form 4 ↗ |
| Eric Dobmeier | Director | 2026-06-11 | A | 15,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Dobmeier | Director | 2026-06-11 | A | 5,500 | 0 | 0 | RSU | Form 4 ↗ |
| Winston Kung | Director | 2026-06-11 | A | 15,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Campbell | Director | 2026-07-08 | A | 7,000 | 4 | 29,470 | Common | Form 4 ↗ |
| David Campbell | Director | 2026-07-08 | D | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Campbell | Director | 2026-07-31 | D | 123,840 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas DiRaimondo | OPTION | 2025-01-02 | — | — | 84,000 | — | $3,691,565 |
| Janeen Doyle | OPTION | 2025-06-02 | — | — | 154,000 | — | 3,124,983 |
| David Campbell | OPTION | 2025-01-02 | — | — | 283,500 | — | 12,459,031 |
| Janeen Doyle | RSU | 2025-05-14 | — | — | 44,000 | — | 995,280 |
| Byron Robinson | OPTION | 2025-01-02 | — | — | 98,000 | — | 4,306,826 |
| Zachariah McIver | OPTION | 2025-01-02 | — | — | 91,000 | — | 3,999,195 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas DiRaimondo | $0 | $0 | $3,691,565 | 0.0% |
| Janeen Doyle | 995,280 | 0 | 3,124,983 | 0.0% |
| David Campbell | 0 | 0 | 12,459,031 | 0.0% |
| Byron Robinson | 0 | 0 | 4,306,826 | 0.0% |
| Zachariah McIver | 0 | 0 | 3,999,195 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Campbell | Option | 83,959 | 14.02 | — |
| Janeen Doyle | RSU | 44,000 | — | 607,200 |
| David Campbell | RSU | 81,000 | — | 1,117,800 |
| Thomas DiRaimondo | RSU | 24,000 | — | 331,200 |
| Janeen Doyle | Option | 35,417 | 12.1 | — |
| David Campbell | Option | 7,381 | 20.24 | — |
| Thomas DiRaimondo | Option | 76,563 | 11.02 | — |
| David Campbell | Option | 185,678 | 11.02 | — |
| Janeen Doyle | Option | 43,594 | 11.02 | — |
| Thomas DiRaimondo | Option | 500 | 20.24 | — |
| David Campbell | Option | 283,500 | 53.24 | — |
| Thomas DiRaimondo | Option | 18,959 | 14.02 | — |
| Thomas DiRaimondo | Option | 84,000 | 53.24 | — |
| Janeen Doyle | Option | 154,000 | 25.01 | — |
| Janeen Doyle | RSU | 26,000 | — | 358,800 |
| Janeen Doyle | Option | 91,000 | 53.24 | — |
Our executive compensation program is designed to achieve a variety of goals, including: attracting and retaining exceptional executive talent; motivating optimal performance that creates long-term company value to align our executives incentives with our stockholders interests; and providing a heavy weighting of performance-based compensation for our executives (with an emphasis on tying compensation to achievement of key corporate objectives) to help properly focus our executives commitment to corporate value growth.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 42,749,182 | 4,574,376 | 46,341 | 90.33% | Passed |
| 2025 | 2025-06-11 | 53,205,989 | 1,150,947 | 15,431 | 97.85% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 90.33%a |
| 2025 | 2025-06-11 | 97.85%b |
a. Approved under the standard stated in the filing — “A "Withhold" vote will have the same effect as an abstention and therefore will have no effect on Proposal 1.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total for Proposal 4 and will have the effect of a vote against each of the proposed frequencies.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 30 : 1 |
|---|---|
| CEO total compensation | $13,506,231 |
| Median employee compensation | $455,932 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ron Barrett, Ph.DIndependent · Board Chair · Compensation (Chair) | $94,063 | $95,475 | $231,241 | $0 | $0 | $420,779 |
| Vickie CappsIndependent · Audit (Chair) | 62,500 | 95,475 | 231,241 | 0 | 0 | 389,216 |
| Jake Simson, Ph.DIndependent · Nominating and Corporate Governance (Chair) | 54,875 | 95,475 | 231,241 | 0 | 0 | 381,591 |
| Winston KungIndependent · Audit | 53,125 | 95,475 | 231,241 | 0 | 0 | 379,841 |
| Alana McNultyIndependent · Audit · Not standing for re-election | 53,125 | 95,475 | 231,241 | 0 | 0 | 379,841 |
| Eric DobmeierIndependent · Compensation | 49,375 | 95,475 | 231,241 | 0 | 0 | 376,091 |
| Natasha HerndayIndependent · Nominating and Corporate Governance | 47,500 | 95,475 | 231,241 | 0 | 0 | 374,216 |
| Sheila Gujrathi, M.DIndependent · Not standing for re-election | 43,750 | 95,475 | 231,241 | 0 | 0 | 370,466 |
| David Campbell, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $326,716 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 8,500 / 8,500 / 8,500 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $458,313 |
| Equity awards (grant-date value) | $763,800 |
| All other compensation | $0 |
| Total cost of the board | $1,222,113 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Janux Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Janux Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | 2024 | Rami Elghandour | $653,288 | $9,342,069 | $10,850,151 | $0 | $21,402,668 |
| 2 | Revolution Medicines, Inc. | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 3 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 4 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 5 | Nuvalent, Inc. | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 6 | Arcus BioSciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 7 | IDEAYA Biosciences, Inc. | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 8 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 9 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 10 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 11 | Xencor, Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 12 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 13 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 14 | Relay Therapeutics, Inc. | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 15 | Zentalis Pharmaceuticals, Inc. | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Arcellx, Inc. | 140% | not disclosed | No | Meridian Compensation Partners |
| Arcus BioSciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| IDEAYA Biosciences, Inc. | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Nuvalent, Inc. | 120% | not disclosed | No | Alpine Rewards |
| Relay Therapeutics, Inc. | 100% | Option 100 | not disclosed | Aon's Human Capital Solutions practice, a division of Aon plc |
| Revolution Medicines, Inc. | 146% | Options 70 · RSU 30 | not disclosed | Compensia |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Xencor, Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Zentalis Pharmaceuticals, Inc. | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, David Campbell | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “SUMMARY COMPENSATION TABLE”. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 2 | Section 01, Byron Robinson | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “SUMMARY COMPENSATION TABLE”. As printed: 5,063,635. Filing ↗machine: span 631359–631368 |
| 3 | Section 01, Janeen Doyle | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “SUMMARY COMPENSATION TABLE”. As printed: 4,669,292. Filing ↗machine: span 613954–613963 |
| 4 | Section 01, Zachariah McIver | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “SUMMARY COMPENSATION TABLE”. As printed: 4,639,495. Filing ↗machine: r8 · c22 · span 622777–622786 |
| 5 | Section 01, Thomas DiRaimondo | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “SUMMARY COMPENSATION TABLE”. As printed: 4,345,469. Filing ↗machine: r5 · c22 · span 596593–596602 |
| 6 | Section 03, Thomas DiRaimondo OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Janeen Doyle OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r9 · c16 · span 714559–714568 |
| 8 | Section 03, David Campbell OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 9 | Section 03, Janeen Doyle RSU | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r8 · c16 · span 708421–708428 |
| 10 | Section 03, Byron Robinson OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 11 | Section 03, Zachariah McIver OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 12 | Section 07, pay ratio | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “CEO Pay Ratio”. As printed: 30 : 1. Filing ↗machine: span 545929–545931 |
| 13 | Section 08, Ron Barrett, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 420,779. Filing ↗machine: t25 · r2 · c8 · span 1135616–1135843 |
| 14 | Section 08, Vickie Capps | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 389,216. Filing ↗machine: t25 · r3 · c8 · span 1138952–1139179 |
| 15 | Section 08, Jake Simson, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 381,591. Filing ↗machine: t25 · r9 · c8 · span 1159344–1159571 |
| 16 | Section 08, Winston Kung | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 379,841. Filing ↗machine: t25 · r7 · c8 · span 1152487–1152714 |
| 17 | Section 08, Alana McNulty | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 379,841. Filing ↗machine: t25 · r8 · c8 · span 1156002–1156229 |
| 18 | Section 08, Eric Dobmeier | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 376,091. Filing ↗machine: t25 · r4 · c8 · span 1142289–1142516 |
| 19 | Section 08, Natasha Hernday | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 374,216. Filing ↗machine: t25 · r6 · c8 · span 1149151–1149378 |
| 20 | Section 08, Sheila Gujrathi, M.D | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 370,466. Filing ↗machine: t25 · r5 · c8 · span 1145812–1146039 |
| 21 | Section 08, David Campbell, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187095 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 02, Maria Dobek 2026-05-11 | Form 4 | 2026-05-13 | 0002032671-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Janeen Doyle 2026-06-02 | Form 4 | 2026-06-04 | 0002069239-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Ronald W. Barrett 2026-06-11 | Form 4 | 2026-06-12 | 0001326330-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Natasha Hernday 2026-06-11 | Form 4 | 2026-06-12 | 0001780547-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Natasha Hernday 2026-06-11 | Form 4 | 2026-06-12 | 0001780547-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Winston Kung 2026-06-11 | Form 4 | 2026-06-12 | 0001666963-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-06-11 | Form 4 | 2026-06-12 | 0001231919-26-000631 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-06-11 | Form 4 | 2026-06-12 | 0001231919-26-000631 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Jake Simson 2026-06-11 | Form 4 | 2026-06-12 | 0001863094-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Jake Simson 2026-06-11 | Form 4 | 2026-06-12 | 0001863094-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Ronald W. Barrett 2026-06-11 | Form 4 | 2026-06-12 | 0001326330-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Vickie Capps 2026-06-11 | Form 4 | 2026-06-12 | 0001248190-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Vickie Capps 2026-06-11 | Form 4 | 2026-06-12 | 0001248190-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Eric Dobmeier 2026-06-11 | Form 4 | 2026-06-12 | 0001202785-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Eric Dobmeier 2026-06-11 | Form 4 | 2026-06-12 | 0001202785-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Winston Kung 2026-06-11 | Form 4 | 2026-06-12 | 0001666963-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, David Campbell 2026-07-08 | Form 4 | 2026-07-10 | 0001864158-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, David Campbell 2026-07-08 | Form 4 | 2026-07-10 | 0001864158-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, David Campbell 2026-07-31 | Form 4 | 2026-07-31 | 0001864158-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 06, 2026 vote | Form 8-K | 2026-06-12 | 0001193125-26-269387 | Item 5.07 · say-on-pay result. As reported: 90.33% (votes for as printed: 42,749,182). Filing ↗ |
| 42 | Section 06, 2025 vote | Form 8-K | 2025-06-13 | 0000950170-25-086284 | Item 5.07 · say-on-pay result. As reported: 97.85% (votes for as printed: 53,205,989). Filing ↗ |
| 43 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 44 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 45 | Section 09b board cost (computed) | Computed | — | — | Cash 458,313 + equity 763,800 + all other 0 = 1,222,113, summed across the director compensation table rows.machine: formula: Σ = 1,222,113 |
| 46 | Arcellx, Inc., Section 10b CEO total | DEF 14A | 2025-04-17 | 0001193125-25-084363 | CEO total compensation as printed in Arcellx, Inc.'s own proxy. As printed: 21,402,668. Filing ↗machine: r2 · c31 · span 471887–471897 |
| 47 | Revolution Medicines, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182453 | CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618 |
| 48 | Janux Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187095 | CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 49 | Crinetics Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 50 | Nuvalent, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001861560-26-000013 | CEO total compensation as printed in Nuvalent, Inc.'s own proxy. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247 |
| 51 | Arcus BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus BioSciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 52 | IDEAYA Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191501 | CEO total compensation as printed in IDEAYA Biosciences, Inc.'s own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319 |
| 53 | Syndax Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197859 | CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331 |
| 54 | Arvinas, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 55 | Beam Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 56 | Xencor, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 57 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 58 | Kura Oncology, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151335 | CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. Filing ↗machine: span 1018180–1018189 |
| 59 | Relay Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186929 | CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162 |
| 60 | Zentalis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001725160-26-000027 | CEO total compensation as printed in Zentalis Pharmaceuticals, Inc.'s own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357 |
| 61 | Section 10a, Crinetics Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 62 | Section 10a, IDEAYA Biosciences, Inc. reciprocity | DEF 14A | — | 0001193125-26-191501 | IDEAYA Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 63 | Section 10a, Relay Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-186929 | Relay Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 64 | Section 10a, Revolution Medicines, Inc. reciprocity | DEF 14A | — | 0001193125-26-182453 | Revolution Medicines, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 65 | Section 10a, Kura Oncology, Inc. reciprocity | DEF 14A | — | 0001193125-26-151335 | Kura Oncology, Inc. names Janux Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 66 | Section 10a, Nuvalent, Inc. reciprocity | DEF 14A | — | 0001861560-26-000013 | Nuvalent, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 67 | Section 10a, Arvinas, Inc. reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 68 | Section 10a, Beam Therapeutics Inc. reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 69 | Section 10a, Zentalis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001725160-23-000078 | Zentalis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 70 | Section 10a, Xencor, Inc. reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 71 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 72 | Section 10a, Arcellx, Inc. reciprocity | DEF 14A | — | 0001193125-25-084363 | Arcellx, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
| 73 | Section 10a, Syndax Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-197859 | Syndax Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Janux Therapeutics. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.